Drug intelligence / Profile preview

amlodipine + rosuvastatin

Development stage
Phase 1
Lead developer
Yuhan
Modality
Small Molecules
Administration
Oral
01

Overview

Amlodipine + rosuvastatin is a fixed-dose combination drug containing two active pharmaceutical ingredients used for the management of patients with both hypertension and dyslipidemia. Amlodipine is an angioselective calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle cells, resulting in vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure. Rosuvastatin is a selective HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the rate-limiting step in cholesterol biosynthesis, leading to decreased LDL-cholesterol levels and prevention of atherosclerosis. The combination addresses two major cardiovascular risk factors simultaneously—high blood pressure and high cholesterol—and has been shown to be more effective at reducing both systolic/diastolic blood pressure and LDL-C compared to either agent alone. It is primarily indicated for cardiovascular risk reduction in patients with concomitant hypertension and hypercholesterolemia[1][3][4][6].

Brand names
Rosuvam
Other names
rosuvastatin + amlodipine
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on amlodipine + rosuvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amlodipine + rosuvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call